Evaluation of the efficacy and safety of colchicine plus methylprednisolone pulse therapy in treatment of Covid-19 patients with ARDS
Design
A clinical trial with control group, double blinded, randomized with random numbers table, phase2 with 80 patients.
Settings and conduct
A clinical trial on 80 patients with progressive covid19 disease admitted in Imam Reza Hospital ICU. Study is randomized and double blinded (both patients and assessor kept blind). in intervention group Methylprednisolone pulse therapy and Colchicine is used in addition to standard treatment in control group.
Participants/Inclusion and exclusion criteria
Covid-19 ICU-admitted patients with moderate to severe ARDS
Intervention groups
Control group: Receiving standard treatment for patients who have ARDS due to covid19 disease including Dexamethasone (8mg daily till 10 days), Interferon beta1(250 microgram till 7 days) and Remdesivir (initial dose: 200mg then 100mg daily)
Intervention group: in addition to receiving standard treatment for patients who have ARDS due to covid19 disease, this group will receive Methylprednisolone pulse therapy (500mg each 12h until 3 days) and Colchicine pill (2mg stat then 1mg daily)
Main outcome variables
Evaluation of the efficacy of colchicine plus methylprednisolone pulse therapy in treatment of Covid-19 patients with Respiratory distress
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20201229049872N1
Registration date:2021-04-22, 1400/02/02
Registration timing:registered_while_recruiting
Last update:2021-04-22, 1400/02/02
Update count:0
Registration date
2021-04-22, 1400/02/02
Registrant information
Name
Mostafa Nematizad
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 4427 9498
Email address
mostafanemati73@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-01-20, 1399/11/01
Expected recruitment end date
2021-06-21, 1400/03/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of the Efficacy and Safety of Colchicine plus Methylprednisolone Pulse Therapy in Treatment of Covid-19 Patients with ARDS
Public title
Efficacy of Colchicine in Treatment of Covid-19
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients with COVID-19 with moderate to severe respiratory failure admitted to ICU wards
Exclusion criteria:
Uncontrolled Diabetes Mellitus
Active bacterial or viral (viral Hepatitis and HIV) or fungal infection
Positive more than 0.5 Procalcitonin or positive bacterial and fungal culture of any specimen of body
Sever Electrolyte disturbance
History of severe reaction to Steroidal products
Active Gastrointestinal bleeding
Age
No age limit
Gender
Both
Phase
2-3
Groups that have been masked
Participant
Outcome assessor
Sample size
Target sample size:
80
Randomization (investigator's opinion)
Randomized
Randomization description
The randomization method used in this study is the use of a table of random numbers
Blinding (investigator's opinion)
Double blinded
Blinding description
Participants in this study, as well as outcome assessors, were kept blind
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of AJA University of Medical Sciences
Street address
AJA University of Medical Sciences, Shahid Etemadzade Ave, West Fatemi Ave
City
Tehran
Province
Tehran
Postal code
1411718541
Approval date
2021-04-20, 1400/01/31
Ethics committee reference number
IR.AJAUMS.REC.1400.011
Health conditions studied
1
Description of health condition studied
Covid 19
ICD-10 code
B97.2
ICD-10 code description
Coronavirus as the cause of diseases classified elsewhere
Primary outcomes
1
Description
Evaluation of the efficacy of colchicine plus methylprednisolone pulse therapy in treatment of Covid-19 patients with Respiratory distress
Timepoint
During the hospitalization period
Method of measurement
According to measurement of secondary outcome variables
Secondary outcomes
1
Description
Duration of hospitalization in ICU
Timepoint
During the hospitalization period
Method of measurement
According to ICU hospitalization and discharge time
2
Description
Duration of being intubated
Timepoint
During the hospitalization period
Method of measurement
Period between intubation and extubation time
3
Description
Duration of staying in hospital
Timepoint
During the hospitalization period
Method of measurement
The difference between the time of admission and the time of discharge
4
Description
Patient's death
Timepoint
During the hospitalization period
Method of measurement
Based on patient file information
5
Description
SOFA score
Timepoint
During the hospitalization period
Method of measurement
Calculation based on defined table
Intervention groups
1
Description
Control group: Receiving standard treatment for patients who have ARDS due to covid19 disease including Dexamethasone (8mg daily till 10 days), Interferon beta1(250 microgram till 7 days) and Remdesivir (initial dose: 200mg then 100mg daily)
Category
Treatment - Drugs
2
Description
Intervention group: in addition to receiving standard treatment for patients who have ARDS due to covid19 disease, this group will receive Methylprednisolone pulse therapy (500mg each 12h until 3 days) and Colchicine pill (2mg stat then 1mg daily)
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Imam Reza Hospital
Full name of responsible person
Ebrahim Hazrati
Street address
Imam Reza hospital - Etemadzadeh Ave - West Fatemi Street
City
Tehran
Province
Tehran
Postal code
1411718539
Phone
+98 21 8609 6350
Email
info@ajaums.ac.i
Web page address
https://imamreza.ajaums.ac.ir/
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Artesh University of Medical Sciences
Full name of responsible person
Ebrahim Hazrati
Street address
AJA University of Medical Sciences, Shahid Etemadzade Ave, West Fatemi Ave
City
Tehran
Province
Tehran
Postal code
1411718541
Phone
+98 21 8609 6350
Fax
+98 21 8833 7919
Email
info@ajaums.ac.ir
Web page address
https://www.ajaums.ac.ir/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Artesh University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Artesh University of Medical Sciences
Full name of responsible person
Ebrahim Hazrati
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Anesthesiology
Street address
AJA University of Medical Sciences, Shahid Etemadzade Ave, West Fatemi Ave
City
Tehran
Province
Tehran
Postal code
1411718541
Phone
+98 21 8609 6350
Email
dr.hazrati.e@gmail.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Artesh University of Medical Sciences
Full name of responsible person
Reza Mosaed
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Pharmacotherapy
Street address
AJA University of Medical Sciences, Shahid Etemadzade Ave, West Fatemi Ave
City
Tehran
Province
Tehran
Postal code
1411718541
Phone
+98 21 8609 6350
Email
reza-mosaed@ajaums.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Artesh University of Medical Sciences
Full name of responsible person
Mostafa Nematizad
Position
Non-faculty general physician
Latest degree
Medical doctor
Other areas of specialty/work
General Practitioner
Street address
AJA University of Medical Sciences, Shahid Etemadzade Ave, West Fatemi Ave
City
Tehran
Province
Tehran
Postal code
1411718541
Phone
+98 21 8609 6350
Email
mostafanemati73@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD